EGFR and neoplasm: Existing clinical trials also suggested that tumor subtypes affected response rate, toxicity, and progression-free survival of targeted agents such as bevacizumab, pemetrexed, and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) [20, 21].